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AbstrAct
High-grade osteosarcoma (OS) is characterized by low incidence, high 
aggressiveness and moderate 5-years survival rate after aggressive poly-
chemotherapy and surgery. Here we used miRNA profiling as a tool to possibly 
predict and monitor OS’s development and therapeutic outcome. First, we evaluated 
the altered expression of selected miRNAs from a case of Giant Cell Tumor (GCT) 
apparently evolved into an OS. We found that most of modulated miRs were associated 
with pathways of bone resorption and osteogenesis. miRNA expression also revealed 
that GCT and OS were distinct tumors. Second, we validated the observed miRNA 
profile in two independent casuistries of ten GCT (not evolved into malignant tumors) 
and sixteen OS patients. Interestingly, we found that miR-181c and other three 
miRNAs identified in the first step of the study were also consistently de-regulated 
in all OS patients. Ectopic expression of miR-181c reduced cell viability and enhanced 
chemotherapeutic-induced cell death of U2OS and SAOS2 cells. These findings indicate 
that: i) miRNAs aberrantly modulated in GCT could be predictive of its development 
into OS and ii) miRNAs expression could be useful to monitor the OS therapeutic 
outcome.
IntroductIon
Osteosarcoma (OS) is the most common primary 
tumor of the bone in young patients. It occurs mainly in 
the second decade with 60% of patients younger than 20 
years old [1]. Since OS occurs very commonly during 
puberty, a time of rapid bone growth and remodeling, it is 
likely that factors related to growth and bone development 
play a role in OS etiology. In particular, during puberty, 
endogenous sex hormones, growth hormones, and 
insulin like growth factor1 (IGF1) levels are at their 
highest, so it is possible that these biological pathways 
play an important role in tumor development [2, 3]. 
Osteosarcomas are classified as malignant mesenchymal 
neoplasms in which the tumor directly produces defective 
osteoid (immature bone). Almost all conventional OS 
are high-grade malignant tumours with poor prognosis 
at the time of inoperable relapse of disease, and 20–25% 
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of the patients have detectable metastases at diagnosis. 
The 5-year survival rate for patients diagnosed with OS 
without presence of metastasis is 60–65%, whereas it is 
only 20–28% for patients with metastasis at diagnosis. 
Even though the survival rate has improved considerably 
after the introduction of neo-adjuvant chemotherapy, the 
need for advances in treatment regimens is still high [4]. 
Giant cell tumor of bone (GCT) represents around 
5% of all primary bone tumors and approximately 20% 
of benign primary bone tumors. The peak incidence is 
between 20 and 45 years of age. GCT typically affects 
the ends of long bones; around 5% affects flat bones, 
especially those of the pelvis [5]. GCTs are characterized 
by the presence of large multinucleated osteoclast-like 
giant cells distributed among mononuclear spindle-like 
stromal cells and other monocytes [6]. The stromal cells 
show positive expression of bone markers [7-14]; thereby 
suggesting a mesenchymal lineage and pre-osteoblast 
phenotype. In vitro and in vivo assays demonstrate that 
the spindle-like stromal cells are actually the neoplastic 
component of the tumor, favoring the hypothesis of a 
mesenchymal origin of GCTs [15]. GCTs can rarely 
transform into a malignant tumor, especially following 
radiation [16]. However, sporadic cases of OS arising from 
benign GCT without irradiation in the primary lesion are 
also reported [17-23].
MicroRNAs (miRNA) are short (17–22 nucleotides) 
noncoding RNAs that modulate gene expression by 
inhibition of translation [24]. Recent computational 
estimations suggest that each miRNA regulates more than 
200 target mRNAs, implying that more than one third of 
protein-coding genes are controlled by miRNAs. miRNAs 
can regulate multiple processes, including metabolism, 
proliferation, differentiation, development, and cell 
death [24], while aberrant miRNAs expression has been 
associated with oncogenesis and tumor suppressor activity 
[25]. Recent studies have suggested miRNA implication 
in skeletal tissue development, like miR-29 for osteoblast 
phenotype attainment [26] or miR-223 for osteoclast 
differentiation [27]. Moreover growing evidences 
propose miRNAs expression as potential biomarkers for 
the diagnosis and prognoses of different tumors [28]. 
Here we aimed to use miRNA profile as a tool to predict 
OS development and therapeutic outcome. The miRNA 
characterization might be of relevant significance in this 
disease because many physiopathological characteristics 
of its initiation and progression are still obscure. In 
particular, in this work, we started our observation from 
a case of GCT evolved into an OS where the altered 
expression of selected miRNAs specifically marked 
that evolution. Interestingly, most of these miRNAs 
are endowed with great impact on bone resorption and 
osteogenesis. Subsequently, we validated that observed 
signature in a consecutive series of GCT and OS admitted 
at our Institute. We also found that ectopic expression 
of miR-181c affected cell viability and enhanced 
chemotherapeutic-induced cell death of osteosarcoma cell 
lines.
results
case presentation
In September 2010 a 22-years-old girl (patient A, 
whose informed consent has been obtained), with a history 
of pain on the left hip for approximately 2 months before 
admission, was referred to Regina Elena National Cancer 
Institute (IRE) in Rome (Fig. 1A). Plain X-ray revealed 
an expansive osteolytic lesion in the proximal left femur 
highly suggestive of GCT (Fig. 1B). A CT-guided needle 
biopsy was performed afterward; the biopsy tissue 
showed a lesion composed of numerous osteoclastic giant 
cells with features identical to stromal cells. There was 
neither atypia nor atypical mitosis. In consideration of the 
morphological and radiographic features, a provisional 
diagnosis of GCT was posed (Fig. 1D). A curettage of 
the lesion was performed and the histological specimen 
confirmed the previous GCT diagnosis (Supplementary 
Fig. 1). On April 2011, 7 months after the surgical 
treatment, the patient relapsed as confirmed by CT (Fig. 
1C) A new biopsy was performed and the GCT diagnosis 
was confirmed (Fig. 1E). Short time relapse was susceptive 
of aggressive behavior. Images and subsequent biopsy 
performed in June 2011, two months after the previous 
one, confirmed the diagnosis of high grade OS (Fig. 1F). 
The patient was treated with neo-adjuvant chemotherapy 
consisting in methotrexate (MTX), Doxorubicin (DOXO) 
and cisplatin (CDDP) (MAP regimen for 2 courses) and 
subjected to a hip resection (extra-articular) with a tumor 
necrosis rate of 65% (Fig. 1G). An adjuvant chemotherapy 
as for poor responder patients was scheduled but the 
patient had a quick and dramatic lung progression of 
disease that led to her death in November 2011. 
miRNA profiling to investigate the clinically 
observed GCT evolution into OS
To investigate at molecular level the apparent 
progression of the GCT towards OS, we assessed the 
expression of 887 human miRNAs from FFPE samples 
representing each pathological stage of the studied case 
(Table 1). We found that 315 miRNAs showed detectable 
levels of expression. Two independent unsupervised 
techniques, Principal Component Analysis (PCA) 
and Hierarchical clustering, were applied to analyze 
the distribution of the selected 315 miRNAs (Fig. 2). 
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Table 1: Case report and control histological samples. Patient A (case report) samples were analyzed as triplicate, while 
Patient B (control) samples were analyzed as duplicate.
Derivation Referred as Histology Origin
Surgery GCT Giant Cell Tumor
Patient A (case report patient)I Biopsy GCTbeta Giant Cell Tumor
II Biopsy OSbeta Osteosarcoma
Surgery CTRL GCT Giant Cell Tumor Patient B
Fig.1: Patient clinical data. A. Case Report time-line. B. GCT, X-ray. C. OS local relapse with pathologic fracture, CT D. GCT 
Haematoxylin/Eosin (H/E) staining: numerous osteoclast-like giant cells scattered among round or spindle mononuclear cells. E: First 
biopsy (after relapse) H/E staining: mononuclear cells proliferation in fibrous tissue with few giant cells. F: Second biopsy (after relapse) 
H/E staining: anaplastic mononuclear cells. G: OS H/E staining: intersecting fascicle of pleomorphic cells with osteoid formation. (D-G 
scale bar: 50µm).
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Interestingly, PCA analysis revealed that GCT and its 
relapse were distinct lesions (Fig. 2A). Considering the 
PCA first component (PC1), as the data most variance, 
we observed significant differences between GCT and 
the subsequent biopsies (Fig. 2A). The analysis of these 
samples highlighted a specific modulation of selected 
miRNAs that occurred between the primary GCT and the 
following relapsed lesions (GCTbeta and OSbeta) (Fig. 
2A). Differently, miRNAs expression profile of GCT from 
patient A showed high correlation with the control sample 
from the independent patient B (Fig. 2A), corresponding 
to a primary GCT that did not developed into an OS. 
Similar results were obtained performing 
hierarchical clustering. Distinct miRNA expression 
profiles distinguished GCT and biopsies of the analyzed 
case report (Fig. 2B). Notably, miRNA expression profile 
of the GCTbeta, which was a histological sign of GCT 
relapse, was more similar to OS than to GCT samples 
from patient A and B. 
Dissection of GCT and OS miRNA expression 
profiles to identify miRNAs involved in the GCT 
malignant evolution
We focused on seventy miRNAs that were 
differentially expressed between GCT and the subsequent 
biopsies (Fig. 3A and Supplementary Table 1). To further 
ascertain the specificity of the modulation, we analyzed 
by RT-PCR the expression of ten out of seventy miRNAs. 
Eight of them exhibited a modulation similar to that 
observed in the array analysis (Table 2).
To investigate the molecular events underlying the 
modulation of the identified miRNAs we performed an 
in silico prediction of their putative targets. This analysis 
was performed separately for up- or down-regulated 
miRNAs comprised in the identified seventy. Interestingly 
a certain number of putative target genes of up-regulated 
miRNAs were involved in osteoclast differentiation, 
Wnt- and TGF-β pathways (Fig. 3B). Considering that 
miRNAs expression leads to their targets degradation, this 
suggests a trend toward a suppression of the osteoclast 
differentiation and, consequently, it could result in an 
aberrant cellular proliferation. Besides, this effect seems 
to be strengthened by the down-regulated miRNAs, that 
targeted these same pathways only marginally (Fig. 3C).
Five miRNAs, miR-193a-5p, miR-181a, miR-181c, 
miR-378, miR-198 involved in pathways known to be 
implicated in the OS development, including TGF-β and 
Wnt, were chosen among the eight validated ones (Table 
2) and were further analyzed. miR-193a-5p, miR-181a, 
miR-181c, miR-378 putative targeted pathways resembled 
those identified for the seventy miRNAs (Supplementary 
Table 2). 
Validation of miR-193a-5p, miR-181a, miR-181c, 
miR-378 down-regulation in OS respect to GCT 
in two IRE casuistries
To assess whether the modulation of the five 
miRNAs fished out from the miRNA profiling of the case 
report could be a feature of OS, we investigated their 
expression in two distinct casuistries, constituted by ten 
GCT and sixteen high grade OS patients enrolled at IRE 
(Table. 3). All the FFPE high-grade OS samples were 
biopsies from naïve patients, thus comparable with the OS 
biopsy of the analyzed case report (patient A).
qRT-PCR analysis revealed that four out of five 
miRNAs identified in the case report analysis, were 
significantly down-regulated in the analyzed OS casuistry 
respect to GCT one (Fig. 4) and the patient A GCT and OS 
(asterisks) are distributed within the values of the GCT’s 
and OS’s samples respectively. 
Correlation between miR-181c level of expression 
in OS patients and therapeutic outcome
To assess the potential association between the 
aberrant miRNAs expression and the patients’ outcome, we 
considered two independent parameters: i) the percentage 
(%) of necrosis induced by the chemotherapeutic treatment 
and ii) the OS relapse. We first observed that there is 
Table 2: miRNAs validation. Validation by RT-PCR of eight miRNAs up- or down- regulated in the case report. Results 
are reported as log2 ratio.
down-regulated miR fold (OSbeta\TCG) array fold (OSbeta\TCG) PCR
miR-378 -2,33 -3,99
miR-181a -2,89    -3,7486
miR-181c -3,53  -1,987
miR-193a -1,1  -1,732
up-regulated miR fold (OSbeta\TCG) array fold (OSbeta\TCG) PCR
miR-155 1,29 0,76
miR-198 3,04 2,6197
miR-483-5p 2,37 0,27
miR-630 2,97 0,4908
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apparently no correlation between the % of necrosis 
induced by chemotherapy and the event of tumor relapse. 
Indeed, as shown in Table 3, a necrosis index >90% is 
not always related to the absence of tumor recurrence. We 
then analyzed the expression of the previously validated 
four miRNAs levels in the OS biopsies and correlated their 
values with the necrosis index assessed by the pathologist. 
As expected, we did not evidence significant predictive 
correlation between any of the miRNAs expression levels 
and the efficacy index of the chemotherapeutic treatment 
(Supplementary Fig. 2). As the necrosis index seemed 
not to be informative, we then evaluated the effect of the 
Fig.2: Patient’s Giant Cell Tumor and Osteosarcoma molecular profiling. A. Unsupervised Principal Component Analysis for 
expressed miRNAs reveals significant distance among subgroups of samples. In particular, the first component shows a different geometric 
representation of GCT samples and the subsequent biopsies (GCTbeta, OSbeta). B. Unsupervised two-way Hierarchical clustering for 
expressed miRNAs grouped samples in clusters of similar expression. Red points have higher expression than mean value while green 
points indicate a lower expression.
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poly-chemotherapy on the expression of the analyzed 
four miRNAs, in order to find a correlation between the 
miRNAs expression and the treatment efficacy. From the 
analysis of miR-193a-5p, miR-181a, miR-181c, miR-
378 expression profiles of the sixteen OS biopsies and 
the matched OS treated samples, we found a statistically 
Fig.3: miRNAs deregulated in patient’s Giant Cell Tumor vs Osteosarcoma. A. Hierarchical Clustering over the selected 
signature of 70 deregulated miRNAs. B. Particulars of up-regulated and C. down-regulated miRNAs after clustering. All replicates of CGT 
samples show a different miRNA profile from the subsequent biopsies.
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Fig.4: miRNA expression levels in IRE Osteosarcoma casuistry. miR-181a, miR193a, miR-181c, miR-378 and miR-198 
expression levels in ten GCTs versus sixteen OSs from IRE casuistry. Four out of five miRNAs are down-regulated in GCTs respect to OSs. 
Asterisks indicate the expression levels relative to case report GCT and case report OS: they are distributed within the values of the GCTs’ 
and OS’ samples respectively.
Table 3: Osteosarcoma patients’ casuistry. Features of OS casuistry from Regina Elena National Cancer Institute, Rome. 
Italy. Therapeutic response and outcome are reported. Tumor relapse score: 0: no relapse. 1: relapse. 2: metastasis.
Sample Age (years) Gender BIOPSY
OSTEOSARCOMA’s 
sIte
Tumor 
relapse
% of 
necrosis
miR-181c 
∆ct mean
1 17 F 9394/I/2007 proximal tibia dx 1, 2 >90% 5,341442
2 21 M 1390/I/2008 distal femur dx 0 >90% 4,403971
3 35 M 10064/I/2008 femur dx 1 >90% 3,211912
4 12 F 3928/I/2008 distal femur 1 <90% 3,04287
5 63 M 3031/I/2009 omerus sx 2 >90% 4,133101
6 15 M 10600/I/2009 femur dist sx 0 <90% 2,206604
7 25 F 8744/I/2010 wrist dx 2 <90% 4,88121
8 20 M 1102/I/2011 distal femur  dx 0 >90% -2,06748
9 22 F 5355/I/2011 pelvis sx 1, 2 <90% 1,531605
10 11 F 9189/I/2006 distal femur dx 1 <90% 1,417068
11 24 M 5082/I/2007 clavicle dx 2 >90% 6,138674
12 18 M 8688/I/2012 proximal tibia  dx 0 <90% 2,729435
13 22 F 5664/I/2012 distal femur sx 0 <90% 2,456497
14 36 M 268/I/2013 distal femur sx 0 >90% -2,94271
15 18 F 2952/I/2013 proximal tibia sx 0 >90% -0,07991
16 12 F 724/I/2013 proximal tibia dx 1 <90% 0,969147
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significant increment of the expression of miR-181c and 
miR-378 after the MAP regimen treatment (Fig. 5A). 
Then, to assess whether there was an impact of 
the miRNA up-regulation on the patient outcome, we 
correlated the expression levels of the analyzed four 
miRNAs with the patient relapse. As shown in Table 3 
the analyzed casuistry included “relapsing” (n=9) and “no 
relapsing” (n=7) patients. The expression levels of the four 
miRNAs in the OS treated samples are shown in Fig. 5B. 
Interestingly, we found that all the four miRNAs levels 
Fig.5: Correlation between miRNA expression levels and patients outcome in IRE Osteosarcoma casuistry. A. miR-
181a, miR193a, miR-181c and miR-378 expression levels before and after the chemo-therapy treatment. A statistically significant up-
regulation in the expression of miR-378 and miR-181c is reported. B. miR-181a, miR193a, miR-181c and miR-378 expression levels in 
the sixteen OS biopsies from the IRE casuistry. Casuistry samples have been divided between «relapsing» and «not-relapsing». miRNAs 
expression levels in these samples are reported in the box-plot. A statistically significant correlation is shown between miR-181c down-
regulation and the OSs’ relapse. 
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upregulated by the chemotherapy (Fig. 5A) remain higher 
in the no-relapsing OS respect to the relapsing ones (Fig. 
5B). Indeed, miR-181c down-regulation was statistically 
significant in “relapsing” tumor patients when compared 
to those “no relapsing”. An informative trend was found 
between the other three miRNAs down-regulation and the 
OSs’ relapse. No statistically significant correlation was 
found between age, gender or histological type and the 
miR-181c expression (data not shown).
Ectopic expression of miR-181c affects cell 
viability of OS cell lines
From the miRNA expression profiling analysis in 
the patients’ casuistries we found a statistically significant 
correlation between the miR-181c expression induced 
by the treatment and the therapeutic outcome. Moreover, 
quantifying miR-181c concentration in all the tumor 
phases of the case report (GCT, OS biopsy and treated 
OS) we revealed a decreasing gradient of expression 
from the GCT through the relapsing OS (Fig. 6A). To 
further analyze miR-181c role, we first performed an in 
silico analysis aimed to identify the miR-181c putative 
targets. As shown in Table 4, we interestingly found 
that among the others, the pathways affected by miR-
181c modulation are the ones of the Cell cycle arrest 
and of the cell cycle negative regulation. We performed 
in vitro experiments aimed to validate this observation. 
We analyzed the expression of miR-193a-5p, miR-181a, 
miR-181c and miR-378 in U2OS osteosarcoma cell line 
after treatment with 1µg/ml and 5µg/ml cisplatin (CDDP) 
Table 4: miR181c putative target genes. “Feature” column reported the pathways hosting the miR-181c putative target 
genes, that are expressed in the “putative targeted genes” column. The pathway analysis has been conducted by the aim of 
Genemania, on the gene targets identified by DIANA microT.
Feature Fdr Genes in network
Genes in 
genome Putative targeted genes
cell cycle arrest 4.82225E-1 13 192
 ATM,NOTCH2,PPM1A,UBC,MAP2K1, 
ZNF268,CUL5,PSMC2,PHOX2B, 
GATA6,CAB39,PKD2,ERN1
activation of MAPKK activity 8.90337E-1 6 44 MAP2K1,TNIK,TAOK1,RAP1A, CRK,RAF1
negative regulation of cell 
cycle 9.036E-1 15 291
ATM,NOTCH2,PPM1A,UBC,MAP2K1, 
ZNF268,CUL5,PSMC2,PHOX2B,FBX05, 
GATA6,CAB39,PKD2,ERN1,PTEN
maintenance of location in 
cell 9.83034E-1 7 91
HSPA5,EPB41L3,ZNF268,CLASP1,
GCC2,ANKRD13C,PKD2
1-phosphatidylinositol-3-
kinase activity 9.83034E-1 3 11 PIK3R3,PIK3CA,ATM
positive regulation of protein 
catabolic process 9.83034E-1 6 68 NEDD4,SH3D19,ZNF268,PTEN,VIP, CREBRF
spindle 9.83034E-1 9 141  CLASP1,PKHD1,KIF3A,FBX05,KIF3A, BIRC6,KIFAP3,PKD2,CALM1
regulation of anoikis 9.83034E-1 4 19 PIK3CA,MCL1,ANKRD13C,ITGA5
phosphatidylinositol 3-kinase 
activity 9.83034E-1 3 12 PIK3R3,PIK3CA,ATM
anoikis 9.83034E-1 4 22 ITGA5,PIK3CA,MCL1,ANKRD13C
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that represents one of the three drugs administered in 
the standardized chemotherapy. As for the OS treated 
patients, CDDP treatment induced miR-181c and the 
other three miRNA expression levels even in the U2OS 
cell line (Supplementary Fig. 3A). We ectopically 
induced miR-181c expression by vector transfection 
(Supplementary Fig. 3B) and evaluated the effect of 
miR-181c overexpression induced both ectopically and 
by CDDP treatment (Supplementary Fig. 3C) on cell 
viability and cell growth. As shown in figure 6, miR-
181c overexpression i) resembles CDDP effect on cell 
viability (Fig. 6B) and cell growth (Fig. 6C) and ii) seems 
to exert a synergistic effect together with CDDP treatment. 
Moreover, as CDDP treatment, miR-181c overexpression 
induced cell cycle arrest, as indicated by the increased 
level of Cdc2 (Tyr-15) phosphorylation and Cyclin D1 
expression reduction (Fig. 6D).
To further complement these evidence we then 
reproduced in vitro the MAP chemotherapeutic regimen 
treating the U2OS and SAOS2 osteosarcoma cell lines, 
ectopically over-expressing miR-181c, with MTX, DOXO 
and CDDP. Interestingly cell viability was affected by 
MAP treatment as well as by miR-181c over-expression 
and the two conditions revealed an additive effect in the 
reduction of the cell viability (figure 6E). Conversely, 
inhibition of miR-181c expression by miRCURY LNA™ 
transfection (Supplementary Fig. 4B), resulted in a slight 
increase of cell proliferation and in a notably reduced 
efficacy of MAP treatment (figure 6F) Altogether these 
findings highlight miR-181c down regulation as an 
alteration that impacts on chemoresistance of OS.
dIscussIon
Osteosarcoma is a primary bone malignancy 
that typically occurs during adolescence but has also 
a second incidence peak in the elderly. The very low 
incidence of the disease and its high fatality do not 
allow methodologically efficient studies and thus many 
physiopathological characteristics of its initiation and 
progression are still obscure. There is therefore need of 
molecular tools endowed with broader diagnostic and 
prognostic potential. In this report, we describe how 
specific miRNA modulation may represent molecular 
biomarkers of OS development. In order to do so, we 
carefully followed-up a case of GCT ascertained in a 
young girl which later transformed itself into an OS lesion. 
McGrath et al., classified GCT which spontaneously 
evolves into malignant tumors within a short period 
and without irradiation as “evolutionary” tumors [29]. 
Twenty-one cases of GCT evolutionary malignancy, with 
the average period of transformation of 9.9 years have 
been reported so far. Among those, seven GCT patients 
progressed into OS [20]. Here we report a case of a GCT 
evolutionary malignancy that evolved into an OS after an 
interval of seven months. We found that GCT and OS of 
the presented case were two distinct tumors considering 
their miRNA expression. We also found that the first 
biopsy after relapse, classified as a GCT, exhibited a 
miRNA expression profile more similar to OS than to that 
of GCT. These findings might have important implications 
in the understanding of the malignant evolution of the 
presented case. First, it might suggest that there were no 
detectable malignant regions in the primary GCT lesion. 
Second, some of the differentially expressed miRNAs 
were already expressed in the first biopsy after relapse, 
whose histological diagnosis was still GCT. This suggests 
that early molecular changes at the level of miRNA 
expression might already occur in apparently benign 
lesions and drive the progression of GCT to OS. Third, 
the analysis of the expression of miRNAs can effectively 
complement and deepen the histological assessment of the 
presented case.
It is becoming increasingly clear that miRNAs, 
which can function either as tumor suppressors or 
oncogenes, feature very accurately the specific stage 
of a given tumor and can predict its evolution [30, 31]. 
In addition to this, miRNAs controlling the expression 
of their mRNA targets can either turn off or on specific 
pathways whose miRNA-mediated alteration plays a 
pivotal role in the malignant progression of a tumor. The 
four miRNAs identified within our profiling analysis 
have already been published in OSs or in other kind of 
tumors. miR-181c down-regulation has been shown to 
be associated with imatinib resistance in chronic myeloid 
leukemia [32], while in neurodegenerative diseases, 
glioblastoma and neuroblastoma (NB) studies it has 
been demonstrated to repress TGFβ1 [33], to attenuate 
self-renewal ability [34] and to inhibit NB cell growth 
and metastasis-related traits through the suppression 
of Smad7 [35] respectively. miR-193a overexpression 
appears to be correlated with OS patients who were good 
responders to ifosfamide treatment [36] and miR-378 can 
function either as an oncogene or a tumor suppressor in 
different types of cancers. Several studies have reported 
that miR-378 was significantly down-regulated in Colon 
Rectal Cancer (CRC). Indeed CRC patients with low 
miR-378 expression had a significantly poorer overall 
survival [37]. Consistently with these evidences, we 
found that these miRNAs were down-regulated in our OS 
casuistry. As for miR-378, the deregulation of miR-181a 
expression in cancer development is reported for different 
types of tumor, even though there is not a univocal 
variation in its expression. For instance, some studies 
demonstrated that it is up-regulated in pancreatic cancer 
and breast cancer [38] [39], and that miR-181a improves 
proliferation and invasion when ectopically expressed in 
in OS cell lines [40]. In our study we found that miR-181a 
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Fig.6: miR-181c overexpression affects osteosarcoma cell viability in vitro. miR-181c expression levels detected by RT-PCR 
in the FFPE GCT, OS biopsy and treated OS of the patient A. B n° of viable U2OS cells transfected with control and pCMV-miR-181c 
vectors after 24h, 48h and 72h from the 5µg/ml CDDP treatment. B. Cell viability measured by ATP-light assay in U2OS cells transfected 
with control and pCMV-miR-181c vectors after 24h, 48h and 72h from the 5µg/ml CDDP treatment. C. P-Cdc2 incremented and Cyclin 
D1 reduced expression levels in U2OS cells overexpressing miR-181c and after 24h from the 5µg/ml CDDP treatment. D. ATP-light assay 
in SAOS 2 and U2OS cells untreated (Veh), treated with MAP poly-chemotherapy regimen (MAP), overexpressing miR-181c (miR-181c) 
or overexpressing miR-181c and treated with MAP regimen. F ATP-light assay in SAOS 2 and U2OS cells miR-181c inhibited (LNA) or 
not inhibited (ctrl), untreated (Veh), or treated with MAP poly-chemotherapy regimen (MAP). Data are reported +/- SD. Asterisks indicate 
statistically significant differences.
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is downregulated in OS respect to GCT but we did not 
find any correlation between its level of expression and 
the OS ability to relapse. This might suggest that it is not 
involved in the response to treatment, as also suggested by 
the in vitro experiments (Supplementary Fig. 4A). miR-
181a over-expression is also reported in OS [30], but it 
is important to note that Jones and colleagues detected 
miR-181a upregulation in OS respect to controls, while 
we compared miR-181a expression in OSs respect to 
GCT. Besides, different groups showed that miR-181a was 
down-regulated in gliomas and aggressive CLL [41] where 
it functions as a tumor suppressor that triggers growth 
inhibition, induces apoptosis and inhibits invasion. 
In silico analysis allowed us to reveal that some 
of the differentially expressed miRNAs identified in 
the analysis of the presented case impinge on TGF-β 
and Wnt-pathways (Fig. 3 and Supplementary Table 
2). These two pathways regulate bone resorption and 
osteogenesis, in particular the Wnt pathway controls 
osteoblast and osteoclast differentiation and osteosarcoma 
invasiveness, while the TGF-β pathway stimulates bone 
and tumor cell proliferation and is associated with high 
grade osteosarcoma [9, 36, 42-45] [46]. Wnt and TGF-
beta inhibition or down regulation, seems to impinge 
osteosarcoma growth ad metastasis[47] [48] suggesting 
that Wnt and TGF-beta signaling inhibitors could 
represent a promising therapeutic strategy. The observed 
down-regulation of miR-193a-5p, miR-181a and miR-
181c is compatible with the engagement of TGF-β- and 
Wnt- pathways along the GCT evolutionary malignancy 
of the presented case. Besides, the correlation between 
the miR-181c overexpression after -and possibly induced 
by- the MAP treatment and the absence of the tumor 
relapse, can be partially explained considering that among 
its putative targets figure genes regulating the cell cycle, 
like GATA6, MAP2K1, PPM1A and Notch2. To point 
out some of the already known roles of these genes and 
their involvement in cancer development, we can mention 
that the transcription factor GATA6 governs the M-phase 
of the cell cycle, and has been found to be up-regulated 
in gastric cancer [49]; MAP2K1 (MEK1) inhibition 
in combination with BMP-2 and BMP-9 represent a 
promising strategy in the treatment of the osteosarcoma 
cells [50] ; Notch2 overexpression has been reported 
in human osteosarcoma biopsy specimens, where the 
Notch pathway inhibition impinge the osteosarcoma cell 
proliferation [51] and finally that the PPM1A phosphatase 
interacts with and dephosphorylates Smad1 [52] leading 
to its activation that promotes p53 induction to suppress 
tumorigenesis [53]. Indeed, we observed cell growth arrest 
in osteosarcoma cell lines as a consequence of the miR-
181c overexpression, induced either ectopically or by 
CDDP treatment.
In line with these findings, a systematic analysis 
of the miRNA targets and the discovery and functional 
validation of their related pathways could be a strong 
rationale to design novel therapeutic approaches to treat 
OSs. This does not necessarily imply the production 
of novel therapeutic compounds but could provide the 
molecular basis for a more tailored use of already existing 
anticancer drugs. It is worth to notice that we validated 
miR-181a, miR-181c, miR-193a-5p and miR-378 different 
modulation between the two casuistries of GCT and high 
grade OS patients. Besides, the trend we found between 
miR-181c down-regulation and OS therapeutic outcome, 
might suggest that the expression of this miRNA could be 
used to evaluate the treatment response This observation 
is supported by in vitro data, where the overexpression of 
miR-181c in a human osteosarcoma cell line, correlates 
with the reduction of cell growth and viability, an effect 
comparable and synergic with the one exerts by CDDP 
treatment. These data suggest that miR-181c could be 
considered a useful indicator in the monitoring of patients 
therapeutic outcome. 
We are aware that the validation in the cohort of 
sixteen naïve patients is partial and requires further studies 
on larger cohorts. However it could represent a starting 
point to i) better and opportunely evaluate GCT relapse 
when they occur, and ii) help in clarifying OS onset, 
development and response to therapy.
Methods
Validation samples
The validation of the miRNA signature was done in 
a consecutive series of ten GCT and sixteen OS patients 
recruited at the Department of Orthopedic surgery at the 
Regina Elena National Cancer Institute in Rome. OS 
patients were aged from 11 to 63, with an average age 
of 23,2 years. 8 were female and 8 were males. All the 
tumors were diagnosed and confirmed as high grade OS.
Features validation
Real-Time PCR (RT-PCR) was used as alternative 
technique to validate eight out of seventy deregulated 
miRNAs on case-report samples. We focused our 
investigation on five out of the eight validated miRNAs, 
miR-193a-5p and miR-181a, miR-181c, miR-378, miR-
198. In particular, miR-193a-5p, miR-181a, miR-181c 
and miR-378 were involved in the same pathways of the 
seventy deregulated ones, accordingly to in silico putative 
target prediction analysis (Supplementary Table 2). The 
RT-PCR of miR-193a-5p and miR-181a, miR-181c, miR-
378, miR-198 was conducted on ten GCT samples and 
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sixteen high-grade OS biopsies samples to evaluate fold 
changes between the two casuistries of lesions.
miRNA profiling 
The miRNA profiling was performed on FFPE 
sections from samples listed in Table 1 and Table 3. Table 
1 reports Patient A specimens from the first (GCT) surgery, 
as well as from the first (GCTbeta) and second (OSbeta) 
biopsy after tumor relapse. Another independent patient, 
corresponding to a primary GCT that did not developed 
into an OS (Patient B) was included in the analysis. 
Patient B was added to compare miRNA differently 
expressed between GCT and OS with their expression in 
a GCT independent patient. Table 3 reports High-grade 
OS casuistry collected at Regina Elena National Cancer 
Institute from 2007 to 2013.
Total RNA was extracted from FFPE samples 
using miRNeasy FFPE (Qiagen), according to the 
manufacturer’s instructions. Agilent’s miRNA Complete 
Labeling and Hyb Kit (Agilent Technologies Inc., US) 
was used to generate fluorescent miRNA, following the 
manufacturer’s instructions. Scanning and image analyses 
were performed using the Agilent DNA Microarray 
Scanner (P/N G2565BA). Feature Extraction Software (V-
10.5) was used for data extraction from raw microarray 
image files using the miRNA_105_Dec-09FE protocol. 
Signal intensities were quintile normalization and log2-
trasformed. Unsupervised Principal Component Analysis 
(PCA) and Hierarchical Clustering were performed 
to individuate differences in subgroups of samples. A 
Student’T-test was used to select the most deregulated 
features between GCT and OS and a false discovery rate 
procedure applied for multiple comparisons, setting the 
level of significance at 5%. The whole bioinformatics 
analysis was performed by MATLAB (The Mathworks 
Inc. Version 7.8). 
Target prediction 
In silico putative target prediction of specific 
miRNAs and pathway analysis were conducted using 
miRWalk 2 (http://zmf.umm.uni-heidelberg.de/apps/zmf/
mirwalk2/). 
Histological analysis
5μm-thick sections were trimmed from each 
formalin fixed paraffin embedded (FFPE) histological 
specimen (tab. 1, 3), re-hydrated and Haematoxylin/Eosin 
stained. Two expert pathologists independently assessed 
the GCT or OS diagnosis.
U2OS and SAOS2 cell lines culture, treatment 
and transfection’s conditions
U2OS and SAOS2 human osteosarcoma cell 
lines were cultured as monolayers at 37°C and 5% CO2 
in DMEM (Invitrogen-Gibco, Carlsbad, CA, USA) 
supplemented with 10% non-heat inactivated FBS (fetal 
bovine serum). U2OS were treated with Cisplatin (TEVA 
Italia, Italy) at 1µg/ml and 5µg/ml. The dose-response 
curve indicates these doses have ineffective and 50% 
effective, respectively, after 24h (data not shown). For 
miR-181c over-expression, U2OS and SAOS2 cells, were 
transfected with the pCMV-miR-181c expression vector 
(miR-181c) and pCMV control vector (CNTR) (Origene 
Technologies, Rockville, MD, US) using Lipofectamine 
2000 (Invitrogen-Gibco, Carlsbad, CA, US) following 
the manufacturer’s instruction. While to inhibit miR-
181c expression U2OS and SAOS2 cells were transfected 
with miRCURY LNA™ microRNA inhibitor (Exiqon, 
Vedbaek, Denmark) using Lipofectamine RNAiMAX 
(Invitrogen-Gibco, Carlsbad, CA, US) following the 
manufacturer’s instruction. Cell growth was evaluated by 
luminescent assay using ATPlite™ Luminescence Assay 
System (PerkinElmer, Whaltman, MA, US).
Cell viability assay
U2OS and SAOS2 cells where miR181c was 
either overexpressed or inhibited and their corresponding 
control were seeded in 96-well plate, 800 cells/well, four 
replicates per point. After 24h, cells were treated with the 
three drugs of the MAP chemotherapy regimen: Cisplatin 
(Teva Italia, srl) 1µg/ml; Doxorubicin (Ebewe Pharma, 
Austria) 0.01µg/ml, Methotrexate (Pfizer, New York, NY, 
US) 0.1µg/ml. The indicated concentrations lied below the 
IC50 values obtained by the single treatment dose-response 
curve of each drug (data not shown). After 24h, cell 
viability was evaluated with the ATPlite™ Luminescence 
Assay System following the manufacturer’s instructions. 
Luminescence was evaluated with the EnSpire® 
Multimode Plate Reader (PerkinElmer, Whaltman, MA, 
USA) and the results were analyzed using the GraphPad 
Prism® software.
Total cellular RNA extraction and RT-PCR 
Total RNA was extracted from U2OS cells using 
Trizol Reagent (Invitrogen-Gibco, Carlsbad, CA, US) 
according to the manufacturer’s instructions. RT-PCR 
quantification of miRNA expression was performed using 
TaqMan MiRNA Assays (Applied Biosystems) according 
to the manufacturer’s protocol RNU48 was used as 
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endogenous controls to standardize miRNA expression. 
All reactions were performed in duplicate.
Western blot
U2OS cells were lysed in UREA buffer and 
protein concentrations were determined by colorimetric 
assay (Bio-Rad, Hercules, CA, US). Western blotting 
was performed using the following primary antibodies: 
mouse monoclonal anti-Cdc2 (Tyr-15) (Santa-
Cruz Biotechnologies, Santa Cruz, CA, US); mouse 
monoclonal anti-Cyclin D1 (Invitrogen-Gibco, Carlsbad, 
CA, US); mouse monoclonal anti-tubulin (Santa-Cruz 
Biotechnologies, Santa Cruz, CA, US). A goat anti-mouse 
secondary antibody HRP-conjugated was used (Bio-Rad, 
Hercules, CA, US). Immuno-stained bands were detected 
by chemiluminescent method (Pierce, Rockford, IL, USA)
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